Chugai Pharmaceutical (4519 JP) shares declined 5% since I published initial bearish note on the company in December. I remain bearish on the name.
Despite a 60% y/y jump in revenue in Q1 2022, the company is still guiding for just 15% y/y revenue growth in 2022. Operating margin has deteriorated in Q1.
Chugai’s significant dependency on COVID-19 drugs amid declining new infections and hospitalizations globally, remain the major overhang on the growth prospects of the company.
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
Unlock all research summaries
Follow top, independent analysts
Receive personalised alerts and emails
Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.